Wuxi Bio (02269) rose more than 5% in the afternoon, up 3.28% to HK$11.98 at the time of writing, with a turnover of HK$393 million.
According to the Wisdom Financial News App, Wuxi Bio (02269) rose more than 5% in the afternoon, up 3.28% to HK$11.98 at the time of writing, with a turnover of HK$393 million.
On the news front, a spokesman for the government of Worcester, USA recently stated that WuXi Biologics had notified the local government that its $300 million expansion program had been suspended. WuXi Biologics responded that this was a normal adjustment within the company and only a temporary pause. WuXi Biologics did not respond to whether this was related to the controversy over the US Biological Safety Act draft, but only stated that, "all bases will have design adjustments during the construction process, which is normal operation."
China Securities Co.,Ltd. (CITIC Securities) stated that the level one investment and financing in the medical sector still needs to be resumed, and downstream demand still needs to improve. Compared with global enterprises, domestic CXO companies still have certain competitive advantages. In recent years, with the rapid development of ADC and polypeptide drugs, the demand for related CXOs has increased rapidly, and sub-sectors such as small nucleic acids and CGT are also expected to usher in rapid development. Companies that match high-end demand in the clinical CRO field are expected to get a higher market share. At present, the overall valuation of the CXO sector is low. in the long term, we are still bullish on the development potential and growth space of the CXO sector.